You are now leaving the Hypermunes.com Web site.

Links to external, non-Talecris Biotherapeutics Internet sites are provided as a courtesy; however, Talecris Biotherapeutics is not responsible for the availability or the content of such Web sites.

Please see our General Conditions of Use for more information.

OK     CANCEL
 

HyperHEP B® S/D [Hepatitis B Immune Globulin (Human)]
postexposure prophylaxis for hepatitis B

HyperHEP B® S/D Postexposure Prophylaxis for Hepatitis B

The Centers for Disease Control and Prevention (CDC) estimates that there are nearly 1.4 million people in the United States who are currently infected with hepatitis B—Stop the threat with HyperHEP B S/D1

For more information, recommendations, and guidelines concerning hepatitis B, visit the CDC—Advisory Committee on Immunization Practices (ACIP).

Hypermunes Vaccine Visual Aid

Imminent Threat

Vaccines can take weeks to build efficacy, which can protect for years. HyperHEP B S/D provides immediate protection. This allows the vaccine the time needed to establish active immunity in high-risk situations, such as2,3:

  • Patients with acute exposure to blood containing HBsAg*
  • Perinatal exposure of infants born to HBsAg- and/or HBeAg-positive mothers
  • Sexual exposure to an HBsAg-positive person
  • Household exposure to persons with acute HBV

Immediate Protection

HyperHEP B S/D contains high titers of hepatitis B antibodies for postexposure prophylaxis, providing rapid immune protection with detectable levels of antibodies that persist for approximately 2 months or longer. When used in combination with a vaccine, a hepatitis B immune globulin such as HyperHEP B S/D offers maximum postexposure immune protection.4,5

According to the World Health Organization (WHO), when used in combination with a vaccine, HyperHEP B S/D can prevent the spread of hepatitis B by 85%-95%6

HyperHEP B S/D IMPORTANT SAFETY INFORMATION

HyperHEP B S/D should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations. Epinephrine should be available.

In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, Hepatitis B Immune Globulin (Human) should be given only if the expected benefits outweigh the risks.

Local pain and tenderness at the injection site, urticaria, and angioedema may occur; anaphylactic reactions, although rare, have been reported following the injection of human immunoglobulin preparations.

Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after Hepatitis B Immune Globulin (Human) administration.

HyperHEP B S/D is made from human plasma. As with all plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses and theoretically, the Creutzfeldt-Jakob (CJD) agent that can cause disease, cannot be totally eliminated. There is also the possibility that unknown infectious agents may be present in such products.

For full Prescribing Information, click here.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

*Hepatitis B surface antigen.

References:

  1. Weinbaum CM, Williams I, Mast EE, et al; Centers for Disease Control and Prevention. Recommendation for identification and public health management of persons with chronic hepatitis B virus infection. MMWR. 2008;57(RR08):1-20.

  2. Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occupational Medicine. 2007;57:552-556.

  3. Immunization Action Coalition. Hepatitis B: questions and answers. http://www.immunize.org/catg.d/p4205.pdf. Accessed June 15, 2009.

  4. Centers for Disease Control and Prevention. Principles of vaccination. http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/prinvac-508.pdf. Accessed June 15, 2009.

  5. HyperHEP B S/D [package insert]. Research Triangle Park, NC: Talecris Biotherapeutics; 2007.

  6. World Health Organization. Guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. http://www.who.int/occupational_Health/activities/5pepguid.pdf. Accessed June 15, 2009.